Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports Pub Date : 2024-12-20 DOI:10.1016/j.ibneur.2024.12.011

Hanane Doumar , Hicham El Mostafi , Aboubaker Elhessni , Mohamed Ebn Touhami , Abdelhalem Mesfioui

{"title":"Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review","authors":"Hanane Doumar , Hicham El Mostafi , Aboubaker Elhessni , Mohamed Ebn Touhami , Abdelhalem Mesfioui","doi":"10.1016/j.ibneur.2024.12.011","DOIUrl":null,"url":null,"abstract":"<div><div>Cannabis sativa is recognized for its chemical diversity and therapeutic potential, particularly in addressing neurodegenerative diseases such as Alzheimer's disease (AD). Given the complexity of AD, where single-target therapies often prove inadequate, a multi-target approach utilizing cannabis-derived compounds may offer promising alternatives. This review first highlights the chemical diversity of cannabis by categorizing its compounds into cannabinoids and non-cannabinoids. It then examines studies investigating the effects of these compounds on AD-related pathological features. By synthesizing existing knowledge, identifying research gaps, and facilitating comparative analysis, this review aims to advance future research and understanding. It underscores cannabis's potential as a multi-target therapeutic strategy for AD, contributing valuable insights to ongoing scientific discussions.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 96-119"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763173/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IBRO Neuroscience Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667242124001192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Cannabis sativa is recognized for its chemical diversity and therapeutic potential, particularly in addressing neurodegenerative diseases such as Alzheimer's disease (AD). Given the complexity of AD, where single-target therapies often prove inadequate, a multi-target approach utilizing cannabis-derived compounds may offer promising alternatives. This review first highlights the chemical diversity of cannabis by categorizing its compounds into cannabinoids and non-cannabinoids. It then examines studies investigating the effects of these compounds on AD-related pathological features. By synthesizing existing knowledge, identifying research gaps, and facilitating comparative analysis, this review aims to advance future research and understanding. It underscores cannabis's potential as a multi-target therapeutic strategy for AD, contributing valuable insights to ongoing scientific discussions.

查看原文本刊更多论文

探索大麻素和非大麻素化合物的多样性及其在阿尔茨海默病中的作用：综述。

大麻因其化学多样性和治疗潜力而得到认可，特别是在治疗阿尔茨海默病（AD）等神经退行性疾病方面。考虑到阿尔茨海默病的复杂性，单靶点治疗往往被证明是不够的，利用大麻衍生化合物的多靶点方法可能提供有希望的替代方法。本综述首先通过将其化合物分为大麻素和非大麻素来强调大麻的化学多样性。然后，它检查了研究这些化合物对ad相关病理特征的影响。本文旨在通过综合现有知识，识别研究空白，促进比较分析，促进未来的研究和理解。它强调了大麻作为阿尔茨海默病多靶点治疗策略的潜力，为正在进行的科学讨论提供了宝贵的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊